Famotidine for Oral Suspension USP — Class III drug recall D-1127-2017
Terminated recall by Lupin Pharmaceuticals Inc., reported 2017-09-13, distributed nationwide. CGMP Deviations
| Recall number | D-1127-2017 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Lupin Pharmaceuticals Inc., Baltimore, MD, United States |
| Recall initiated | 2017-05-02 |
| Classified | 2017-09-01 |
| Reported by FDA | 2017-09-13 |
| Terminated | 2018-03-28 |
| Distributed | Nationwide (US) |
| Quantity | 12,888 bottles |
| Reason classes | cgmp |
| NDC | 68180-0150, 68180-0150-01 |
| Lot numbers | 07/18, G606950 |
Product
Famotidine for Oral Suspension USP, 40 mg/5 mL, 50 mL bottle, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202; Manufactured by: Lupin Limited, Goa 403 722 INDIA, NDC 68180-150-01
Reason for recall
CGMP Deviations
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-1127-2017. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.